[go: up one dir, main page]

PE20011030A1 - Combinaciones farmaceuticas que comprenden tegaserod y omeprazol - Google Patents

Combinaciones farmaceuticas que comprenden tegaserod y omeprazol

Info

Publication number
PE20011030A1
PE20011030A1 PE2000001312A PE0013122000A PE20011030A1 PE 20011030 A1 PE20011030 A1 PE 20011030A1 PE 2000001312 A PE2000001312 A PE 2000001312A PE 0013122000 A PE0013122000 A PE 0013122000A PE 20011030 A1 PE20011030 A1 PE 20011030A1
Authority
PE
Peru
Prior art keywords
alkyl
halogen
antagonists
receptor
anodycle
Prior art date
Application number
PE2000001312A
Other languages
English (en)
Inventor
Hans-Jurgen Pfannkuche
Stephan Anthony Billstein
Peter Dumovic
Nicola Franco
Mark Thomas Iwicki
Wilusz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20011030A1 publication Critical patent/PE20011030A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UNA COMBINACION QUE COMPRENDE: a) UN COMPUESTO AGONISTA PARCIAL DEL RECEPTOR 5-HT4 DE FORMULA I; DONDE R1 ES H, ALQUILO C1-C6, CARBONILO, BENZOILO, FENILALQUILCARBONILO C1-C4, R5 ES H, HALOGENO, ALQUILO C1-C6, OH, NITRO, AMINO, ALQUILAMINO C1-C6, ALQUILCARBONILAMINO, SO2NRaRb ; Ra Y Rb SON H, ALQUILO C1-C6, CIANO, TRIMETILSILILO, ALQUILO C1-C6, ENTRE OTROS; R6 ES H, CUANDO R5 ES OH R6 ES H, HALOGENO; Z ES -CR4=; R4 ES H, HALOGENO, OH, ALQUILO C1-C6; R7 ES H, HALOGENO, ALQUILO C1-C6; X-Y ES -CR8=N- o -CH(R8)-NH-; R8 ES H, ALQUILO C1-C6; B ES UN GRUPO a; n ES 1-2; A1 ES C=O, CH2; X1 ES S; NR11; R11 ES H, ALQUILO C1-C6 ENTRE OTROS; TAL COMO TEGASEROD (3-(5-METOXI-1H-INDOL-3-IL-METILEN)-N-PENTILCARBAZIMIDAMIDA); b) UN COAGENTE SELECCIONADO A PARTIR DE ANTAGONISTAS DEL RECEPTOR 5-HT3, AGONISTAS O ANTAGONISTAS DEL RECEPTOR 5-HT4, AGONISTAS DEL RECEPTOR DE SOMATOSTATINA, ANTAGONISTAS DEL RECEPTOR HISTAMINA H2, INHIBIDORES DE BOMBA DE PROTONES, AGENTES ANTIESPASMODICOS Y ANTIMUSCARINICOS, ANTIDEPRESIVOS TRICICLICOS, ANTAGONISTAS DEL RECEPTOR COLECISTOQUININA, ENTRE OTROS. LA COMBINACION PUEDE SER UTIL PARA REGULAR, ESTABILIZAR, NORMALIZAR LA MOVILIDAD GASTROINTESTINAL ALTERADA, DESORDENES ABDOMINALES
PE2000001312A 1999-12-10 2000-12-07 Combinaciones farmaceuticas que comprenden tegaserod y omeprazol PE20011030A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45838899A 1999-12-10 1999-12-10

Publications (1)

Publication Number Publication Date
PE20011030A1 true PE20011030A1 (es) 2001-10-31

Family

ID=23820591

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001312A PE20011030A1 (es) 1999-12-10 2000-12-07 Combinaciones farmaceuticas que comprenden tegaserod y omeprazol

Country Status (30)

Country Link
EP (3) EP1286668B1 (es)
JP (1) JP2003523324A (es)
KR (1) KR100765579B1 (es)
CN (2) CN1875966A (es)
AR (1) AR026916A1 (es)
AT (1) ATE293971T1 (es)
AU (2) AU778869B2 (es)
BR (1) BR0016275A (es)
CA (1) CA2388959A1 (es)
CO (1) CO5261535A1 (es)
CZ (1) CZ300690B6 (es)
DE (1) DE60019814T2 (es)
DK (1) DK1286668T3 (es)
ES (1) ES2240229T3 (es)
HU (1) HUP0301122A3 (es)
IL (2) IL149496A0 (es)
MX (1) MXPA02005695A (es)
MY (1) MY133423A (es)
NO (1) NO20022680L (es)
NZ (2) NZ531489A (es)
PE (1) PE20011030A1 (es)
PL (1) PL202201B1 (es)
PT (1) PT1286668E (es)
RU (1) RU2264215C2 (es)
SG (1) SG152025A1 (es)
SK (1) SK8062002A3 (es)
TR (1) TR200402293T2 (es)
TW (1) TWI263496B (es)
WO (1) WO2001041748A2 (es)
ZA (1) ZA200204493B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1284732A2 (en) * 2000-05-18 2003-02-26 Glaxo Group Limited Method for treating functional dyspepsia using alosetron
GB0209481D0 (en) * 2002-04-24 2002-06-05 Novartis Ag Organic compounds
KR20050094843A (ko) 2003-01-13 2005-09-28 다이노젠 파마세우티컬스, 인코포레이티드 욕지기, 구토, 구역질 또는 이들의 조합을 치료하는 방법
GB0307440D0 (en) * 2003-03-31 2003-05-07 Novartis Ag Organic compounds
RS20050868A (en) * 2003-05-27 2007-08-03 Altana Pharma Ag., Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility
US20050090554A1 (en) * 2003-09-12 2005-04-28 John Devane Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists
US7820690B2 (en) 2004-03-19 2010-10-26 Solvay Pharmaceuticals Gmbh Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist
AU2005261778A1 (en) * 2004-07-14 2006-01-19 Novartis Ag Combination of DPP-IV inhibitors and compounds modulating 5-HT3 and/or 5-HT4 receptors
EP1853256A2 (en) * 2005-01-31 2007-11-14 Novartis AG Organic compounds
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
EP1987009A1 (en) 2006-01-30 2008-11-05 Euro-Celtique S.A. Cyclourea compounds as calcium channel blockers
KR20090019914A (ko) * 2006-06-15 2009-02-25 노파르티스 아게 테가세로드를 단독으로 포함하거나 또는 양성자 펌프 억제제와 조합으로 포함하는, 위 손상의 치료 또는 예방용 조성물
WO2008130464A1 (en) 2007-02-09 2008-10-30 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
LT3354276T (lt) * 2007-11-13 2020-04-27 Meritage Pharma, Inc. Kompozicijos, skirtos skrandžio ir žarnyno uždegimo gydymui
US20090123390A1 (en) 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2017220990A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 antibodies
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11858996B2 (en) 2016-08-09 2024-01-02 Kymab Limited Anti-ICOS antibodies
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
TW202313682A (zh) 2021-05-18 2023-04-01 英商凱麥博有限公司 抗icos抗體之用途
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
WO2023222854A1 (en) 2022-05-18 2023-11-23 Kymab Limited Uses of anti-icos antibodies
FR3144752A1 (fr) 2023-01-10 2024-07-12 Song Huang Utilisation de polysulfate de pentosane pour le traitement de la toux seche

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
EP0617620B1 (en) * 1991-12-21 1998-09-09 Smithkline Beecham Plc Use of 5-ht4 - antagonists for the manufacture of a medicament for the treatment of urinary incontinence
GB9214184D0 (en) * 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
US6156771A (en) * 1997-08-28 2000-12-05 Rubin; Walter Method for alleviation of lower gastrointestinal disorders in a human patient
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
DE60019814D1 (de) 2005-06-02
IL149496A (en) 2009-12-24
WO2001041748A3 (en) 2002-12-19
MXPA02005695A (es) 2002-09-18
CN1875966A (zh) 2006-12-13
CN1409634A (zh) 2003-04-09
IL149496A0 (en) 2002-11-10
PT1286668E (pt) 2005-08-31
NZ531489A (en) 2005-09-30
BR0016275A (pt) 2002-08-27
CZ20021967A3 (cs) 2002-08-14
SG152025A1 (en) 2009-05-29
MY133423A (en) 2007-11-30
RU2002118316A (ru) 2004-02-20
ES2240229T3 (es) 2005-10-16
AU2005200797B2 (en) 2008-01-24
DK1286668T3 (da) 2005-08-15
ZA200204493B (en) 2003-09-29
CN1310644C (zh) 2007-04-18
NZ566800A (en) 2009-11-27
NO20022680L (no) 2002-08-12
HUP0301122A3 (en) 2005-03-29
EP1286668B1 (en) 2005-04-27
KR20030016208A (ko) 2003-02-26
EP1913944A1 (en) 2008-04-23
ATE293971T1 (de) 2005-05-15
PL202201B1 (pl) 2009-06-30
SK8062002A3 (en) 2003-04-01
PL355663A1 (en) 2004-05-04
CZ300690B6 (cs) 2009-07-15
AU778869B2 (en) 2004-12-23
EP1286668A2 (en) 2003-03-05
HUP0301122A2 (hu) 2003-08-28
DE60019814T2 (de) 2006-03-02
TWI263496B (en) 2006-10-11
EP1488788A1 (en) 2004-12-22
AU2005200797A1 (en) 2005-03-17
NO20022680D0 (no) 2002-06-06
CA2388959A1 (en) 2001-06-14
WO2001041748A2 (en) 2001-06-14
KR100765579B1 (ko) 2007-10-09
RU2264215C2 (ru) 2005-11-20
JP2003523324A (ja) 2003-08-05
AR026916A1 (es) 2003-03-05
AU2672801A (en) 2001-06-18
TR200402293T2 (tr) 2004-10-21
CO5261535A1 (es) 2003-03-31

Similar Documents

Publication Publication Date Title
PE20011030A1 (es) Combinaciones farmaceuticas que comprenden tegaserod y omeprazol
PE20010854A1 (es) USO DE DERIVADOS DE PIRIMIDINA 4 SUSTITUIDOS COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO mGluR1
PE20040935A1 (es) Analogos de 2-quinazolina sustituida-4-ilamina como moduladores de los receptores de capsaicina
PE20060401A1 (es) Derivados de n-(2-bencil)-2-fenil-butanamidas y propanamidas como moduladores del receptor de androgeno
PE20050525A1 (es) Derivados de pirazol sustituido y compuestos relacionados como antagonistas del receptor de bradiquinina b1
PE20011265A1 (es) Novedosos derivados diamino sustituidos
PE20081316A1 (es) COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA
PE20030471A1 (es) Compuesto de imidazopiridin como moduladores del receptor 5-ht4
NO20050429L (no) Substituert kinolin-CCR5-reseptorantagonister
ES2161231T3 (es) Compuestos heterociclicos como antagonistas de bradiquinina.
PE20050193A1 (es) Compuestos heterociclicos utiles como activadores de nurr-1
PE20020720A1 (es) Derivados benzimidazol y piridilimidazol como ligandos para receptores gabaa
PE20040758A1 (es) Compuestos 3-aminopirazoles n-sustituidos como inhibidores de la enzima tirosin-quinasa asociada al receptor pdgf y procedimientos para su preparacion
DK1173433T3 (da) Cyanopyrroler som progesteronreceptoragonister
PE20021094A1 (es) Derivados de ciclohexano-1,4-diamina sustituidos
ATE401066T1 (de) Methoden zur behandlung der essstörungen
ES2171675T3 (es) Derivados de diarildiamina y su uso como (ant)agonistas de los receptores delta opioides.
ATE325119T1 (de) 3-substituierte oxindol-beta-3-agonisten
DE60222396D1 (de) N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste
PE20061297A1 (es) Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
PE44297A1 (es) Compuestos de 3-dimetilamino-2-metilfenilimino imidazolidina con actividad como agonistas de o1l para el tratamiento de la incontinencia urinaria
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
AR037065A1 (es) Una composicion farmaceutica en base a bloqueadores de receptores 5ht3 y 5ht4, inhibidores de la bomba de protones y antagonistas de receptores de h2, util para tratar los desordenes gastrointestinales
PE20060689A1 (es) Derivados de sulfonamidas como antagonistas de receptores orexina 2
PE20060604A1 (es) Derivados del tetrahidronaftaleno como agentes antiinflamatorios y procedimiento para su preparacion

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed